Sertralilne, paroxetine and venlafaxine in refugee post traumatic stress disorder with depression symptoms
Smajkić, A.; Weine, S.; Durić-Bijedić, Z.; Boskailo, E.; Lewis, J.; Pavković, I.
Medicinski Arhiv 55(1 Suppl 1): 35-38
2001
ISSN/ISBN: 0025-8083 PMID: 11795192 Document Number: 7604
The authors describe the use of three new antidepressants: Sertralilne, Paroxetine and Venlafaxine in treating Posttraumatic Stress Disorder and symptoms of Depression in adult Bosnian refugees victims of ethnic cleansing. 32 Bosnian refugees with PTSD and symptoms of Depression presenting for treatment of the mental health consequences of surviving ethnic cleansing, participated in a case series study. All subjects completed open trials of Sertraline (15), Paroxetine (12) or Venlafaxine (5), with standard clinical doses. Overall, Sertraline and Paroxetine yielded statistically significant improvement at 6 weeks in the total PTSD symptom severity, in each symptom cluster, in Beck Depression Inventory and in Global Assessment of Functioning. Venlafaxine produced statistically significant improvement at 6 weeks in the total PTSD symptom severity, in each symptom cluster and in Global Assessment of Functioning but did not yield significant improvement in symptoms of depression and had a high rate of side effects.
Document emailed within 1 workday
